Condition (MeSH)
Blepharitis
ClinicalTrials.gov lists 64 trials for Blepharitis or a narrower condition beneath it. Merck Sharp & Dohme LLC has the most among industry and government lead sponsors, with 7.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
62 of the 64 trials are tagged with Blepharitis itself; the rest are tagged with a narrower condition beneath it.
When did Blepharitis trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 5 |
| 2023 | 4 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 1 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 11 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 9 months across 45 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Blepharitis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 13 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |
| Phase 4 | 11 |
| Not applicable | 20 |
| Observational | 7 |
How many Blepharitis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 41 |
| Terminated | 5 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Blepharitis trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 7 |
| Tarsus Pharmaceuticals, Inc. | 4 |
| Alcon Research | 2 |
| Nicox Ophthalmics, Inc. | 2 |
| Adapt Produtos Oftalmológicos Ltda. | 1 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Blepharitis? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Lotilaner | 2 |
| Tea Tree Oil | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Azithromycin | 9 |
| Azithromycin Ophthalmic Solution, 1% | 3 |
| TP-03 Vehicle | 3 |
| Dexamethasone/Dexamethasone acetate | 2 |
| TP-03 | 2 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Blepharitis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Bladder Cancer | 1 | 1 |
| COVID-19 | 1 | 1 |
| Covid-19 | 1 | 1 |
| Diabetic retinopathy | 1 | 1 |
| Dyspnoea | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Blepharitis? (52)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). | Cornea | 2023 | Yes |
| Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2). | Ophthalmology | 2023 | Yes |
| Role of Blepharoexfoliation in Demodex Blepharitis: A Randomized Comparative Study. | Cornea | 2023 | Yes |
| Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies. | Eye & contact lens | 2023 | Yes |
| Efficacy of Topical Ivermectin 1% in the Treatment of Demodex Blepharitis. | Cornea | 2022 | Yes |
Showing 5 of 52 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.